{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-008819","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2023-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.046594+00:00","generated_at":"2026-06-20T03:30:22.341259+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CytoSorbents preliminary FY2022 revenue $34.7M; core product sales constant currency down 4.6%","bullets":["Preliminary FY2022 total revenue $34.7M vs $43.2M in 2021; product sales $29.4M (Q4 $7.6M, +18% sequentially).","Core non-COVID product sales $29.1M; constant currency ~$32.2M, down 4.6% from 2021.","Q4 2022 core product sales constant currency $8.5M (+6% YoY); cumulative CytoSorb treatments >195,000 (+20% YoY).","Cash $23.8M at year end; $5M Bridge Bank term loan in Dec; expects product gross margins 75-80% in 2023.","STAR-T trial for DrugSorb-ATR: 1/3 of 120 patients enrolled; DSMB cleared; completion expected summer 2023; FDA submission planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-008819","json":"https://secwatch.observer/filing/0001104659-23-008819.json","markdown":"https://secwatch.observer/filing/0001104659-23-008819.md","text":"https://secwatch.observer/filing/0001104659-23-008819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923008819/0001104659-23-008819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923008819/tm234948d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T03:30:22.341259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1f0f3bcfcd2a90f670bb1bb7b3be7a72bf58269","claim":"Cytosorbents Corp reported preliminary unaudited full year 2022 results: revenue approximately $34.7 million.","evidence_excerpt":"Preliminary unaudited 2022 Total Revenue, which includes Product Sales and Grant Revenue, was approximately $34.7 million versus $43.2 million in 2021, and $24.9 million in pre-pandemic 2019","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923008819/0001104659-23-008819-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"preliminary unaudited full year 2022"},{"label":"Revenue","value":"approximately $34.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"ff630877e0e237b03af65816fc33842df02c4219","claim":"Cytosorbents Corp reported preliminary unaudited fourth quarter 2022 results: revenue approximately $9.4 million.","evidence_excerpt":"Q4 2022 Total Revenue was approximately $9.4 million versus $10.8 million in Q4 2021, and versus $7.4 million in pre-pandemic Q4 2019","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923008819/0001104659-23-008819-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"preliminary unaudited fourth quarter 2022"},{"label":"Revenue","value":"approximately $9.4 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}